Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 1
1988 1
1991 2
1992 2
1993 1
1994 1
1995 2
1996 1
1997 4
1998 2
1999 2
2000 3
2001 2
2002 3
2003 3
2004 3
2005 2
2006 2
2007 3
2008 11
2009 8
2010 13
2011 7
2012 13
2013 17
2014 15
2015 12
2016 17
2017 20
2018 11
2019 4
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

165 results
Results by year
Filters applied: . Clear all
Page 1
The economics of adalimumab for ulcerative colitis.
Xie F. Expert Rev Pharmacoecon Outcomes Res 2015. PMID 25817776
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF-α blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. ...
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab,
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B, et al. Inflamm Bowel Dis 2018. PMID 29718241
BACKGROUND: Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α (anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative colitis (UC) is limited. ...
BACKGROUND: Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α (anti-TNFα) and oral Janus kinase inhibitor (JAKi) th …
Primary care management of ulcerative colitis.
Davis SC, et al. Nurse Pract 2018. PMID 29206681
Ulcerative colitis (UC) is an inflammatory bowel disease marked by mucosal inflammation. UC has an impact on quality of life and places a financial burden on the healthcare system. ...
Ulcerative colitis (UC) is an inflammatory bowel disease marked by mucosal inflammation. UC has an impact on quality of life a
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease
Vande Casteele N, et al. Gastroenterology 2015 - Clinical Trial. PMID 25724455
BACKGROUND & AIMS: Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). ...
BACKGROUND & AIMS: Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and u
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
Stawowczyk E and Kawalec P. Pharmacoeconomics 2018. PMID 29260508 Free PMC article.
BACKGROUND: Ulcerative colitis (UC) is a chronic autoimmune inflammation of the colon. The condition significantly decreases quality of life and generates a substantial economic burden for healthcare payers, patients and the society in which they live. ...
BACKGROUND: Ulcerative colitis (UC) is a chronic autoimmune inflammation of the colon. The condition significantly decreases q …
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
Williams JG, et al. Lancet Gastroenterol Hepatol 2016 - Clinical Trial. PMID 27595142 Free PMC article.
BACKGROUND: Infliximab and ciclosporin are of similar efficacy in treating acute severe ulcerative colitis, but there has been no comparative evaluation of their relative clinical effectiveness and cost-effectiveness. ...The primary outcome was quality-adjusted survival-ie, the area under the curve (AUC) of scores from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) completed by participants at baseline, 3 months, and 6 months, then every 6 months from 1 year to 3 years. ...
BACKGROUND: Infliximab and ciclosporin are of similar efficacy in treating acute severe ulcerative colitis, but there has been …
Ulcerative Colitis Treatment Patterns and Cost of Care.
Null KD, et al. Value Health 2017. PMID 28577692 Free article.
OBJECTIVES: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). ...
OBJECTIVES: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), ad …
Early Surgical Intervention for Acute Ulcerative Colitis Is Associated with Improved Postoperative Outcomes.
Leeds IL, et al. J Gastrointest Surg 2017. PMID 28819916 Free PMC article.
BACKGROUND: Timing of surgical intervention for acute ulcerative colitis has not been fully examined during the modern immunotherapy era. ...The purpose of this study was to evaluate outcomes according to timing of urgent surgery for acute ulcerative colitis. METHODS: All non-elective total colectomies in ulcerative colitis patients were identified in the National Inpatient Sample from 2002 to 2014. ...
BACKGROUND: Timing of surgical intervention for acute ulcerative colitis has not been fully examined during the modern immunot …
Ulcerative colitis-associated hospitalization costs: a population-based study.
Coward S, et al. Can J Gastroenterol Hepatol 2015. PMID 26079072 Free PMC article.
BACKGROUND: Hospitalization costs for ulcerative colitis (UC) following the introduction of infliximab have not been evaluated. ...
BACKGROUND: Hospitalization costs for ulcerative colitis (UC) following the introduction of infliximab have not been evaluated …
Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C, et al. Expert Rev Pharmacoecon Outcomes Res 2018. PMID 29192530
OBJECTIVES: Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. ...
OBJECTIVES: Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and …
165 results
Jump to page
Feedback